Incidence of Type 2 diabetes in England and its association with baseline impaired fasting glucose: the Ely study 1990-2000.

AIM: To determine the incidence of Type 2 diabetes and to examine the effect of different cut-points for impaired fasting glucose (IFG) on diabetes incidence. METHODS: Population-based longitudinal study (1990-2000) with clinical, anthropometric and biochemical measurements, including an oral glucose tolerance test (OGTT), in 1040 non-diabetic adults aged 40-69 years at baseline. Baseline glucose status was defined as normoglycaemia < 5.6, IFG-lower 5.6-6.0 and IFG-original 6.1-6.9 mmol/l. The all-IFG group included fasting glucose values of 5.6-6.9 mmol/l. RESULTS: The 10-year cumulative incidence of diabetes was 7.3 per 1000 person-years. Diabetes incidence was 2.4 [95% confidence interval (CI) 1.2, 4.8], 6.2 (4.0, 9.8) and 17.5 (12.5, 24.5) per 1000 person-years in those with normoglycaemia, IFG-lower and IFG-original, respectively. Compared with normoglycaemia, the age/sex-adjusted risk [hazard ratio (HR) and 95% CI] for incident diabetes was greatest in the IFG-original category (HR 6.9; 3.1, 15.2) and increased to a lesser degree in the IFG-lower (HR 2.5; 1.1, 5.7) and all-IFG categories (HR 4.1; 1.9, 8.7). When adjusted for confounding factors, the magnitude and direction of associations persisted, with HR 1.9, 4.4 and 2.9, for the categories IFG-lower, IFG-original and all-IFG, respectively. CONCLUSIONS: Diabetes incidence is more strongly related to IFG defined as fasting glucose between 6.1 and 6.9 mmol/l than to the lower category of 5.6-6.0 mmol/l, or entire range of 5.6-6.9 mmol/l. Future studies should examine the association of IFG with cardiovascular outcomes, but for diabetes risk our study supports the use of the IFG cut-point at 6.1 mmol/l.     

The UK Diabetes Research Network--an opportunity and a challenge.

The Department of Health has funded a national diabetes network to support clinical research. The network will facilitate recruitment into clinical trials and has been widely welcomed by clinicians. However, if the network is to reach its full potential, all those involved will need to advocate a change in attitude towards clinical trials and research, encouraging participation and contribution of data. Clinicians need to be willing to take a proactive view about research studies, and to encourage patients to adopt a positive and altruistic attitude towards trial participation. The future of trials and other important clinical research in the UK may depend on it.     

Time and cost involved in the care of newly registered patients with diabetes mellitus and other lifestyle diseases at diabetes clinics in Japan (JDDM 4).

AIMS: To study the time and cost involved in the care of newly registered outpatients with Type 2 diabetes mellitus (DM), compared with patients with hypertension and/or hyperlipidaemia (HTL). METHODS: A total of 313 patients with DM and 58 patients with HTL without diabetes were registered on their first visits to 11 diabetes clinics across Japan. The time and cost involved in their care was recorded over the following 5 months. RESULTS: In the first 3 months, there was an extensive time commitment to both groups. The time spent by physicians was 1.5 times longer for DM than for HTL. The total care time spent by all the care providers for DM was twice that for HTL. The cost of DM care was twice that for HTL, with the cost of medicines excluded. However, half of the cost for DM was for laboratory tests. When these were excluded, and the remaining cost divided by the time spent, the amount for DM was half of that for HTL. Over the 5 months, mean glycated haemoglobin (HbA(1c)) in DM patients improved from 8.0% to 6.5%, and 72% of DM patients achieved the glycaemic target of HbA(1c) < or = 6.5%. CONCLUSIONS: DM care in a diabetes clinic requires a great deal more time and resources than HTL to achieve the best outcome. An educational system for self care, presently lacking in the primary care setting in Japan, would improve glycaemic control for DM patients in the community.     

Increased glucose excursion in cystic fibrosis and its association with a worse clinical status

BACKGROUND: Abnormal glucose tolerance is a frequent co-morbidity in cystic fibrosis patients (CF), and is associated with a worse prognosis. The objectives are to investigate (a) the relative contribution of insulinopenia and insulin resistance (IR) for glucose tolerance and (b) the association between various glucose parameters and CF clinical status. METHODS: Oral glucose tolerance tests were performed in 114 consecutive CF patients not known to be diabetic as well as 14 controls similar for age and BMI. RESULTS: Abnormal glucose tolerance was found in 40% of patients with CF: 28% had impaired glucose tolerance (IGT) and 12% had new cystic fibrosis related diabetes (CFRD). Compared to control subjects, all CF patients were characterized by an increased glucose excursion (AUC). While reduced early insulin release characterised CF, IGT and CFRD patients also present IR thus both mechanisms significantly contribute to glucose tolerance abnormalities. Increased glucose AUC and reduced early insulin release but not glucose tolerance categories were associated with a reduced pulmonary function (FEV(1)). CONCLUSION: In CF, early insulin secretion defect but also IR contribute to glucose intolerance. Early in the course of the disease, increased glucose AUC and reduced early insulin secretion are more closely associated with a worse clinical status than conventional glucose tolerance categories.     

社区人群糖尿病知识知晓率的描述性及分析性研究

目的了解社区人群对糖尿病知识知晓情况,为城镇居民进行糖尿病干预研究提供依据.方法对广州市荔湾区25岁以上常住居民进行随机抽样问卷,对资料作描述性和分析性研究.结果糖尿病知识知晓情况在年龄、性别、文化程度、糖尿病家族史、糖尿病患病史分布上有显著性差异.多因素分析显示:性别、年龄、文化程度、糖尿病家族史、糖尿病患病史、体力劳动强度、脑力劳动强度、收缩压与糖尿病知识知晓率密切相关,其比值比分别为1.239,0.990,1.223,2.752,1.897,1.373,0.916,0.884和0.996.结论该地区人群的糖尿病知识知晓率较低,要广泛开展全民特别是老年人、男性和文化程度较低人群的糖尿病知识宣传教育.     

妊娠期糖耐量受损与妊娠结局的关系

①目的　探讨妊娠期糖耐量受损 (GIGT)对妊娠结局的影响。②方法　以妊娠期GIGT孕妇 1 31例(GIGT组 ) ,妊娠期糖尿病 (GDM)孕妇 1 6 6例 (GDM组 ) ,糖耐量正常孕妇 1 6 0例 (正常对照组 )为研究对象 ,对孕妇及其围生儿结局进行对比研究。③结果　GIGT组及GDM组妊娠高血压综合征、巨大儿、羊水过多、胎膜早破、剖宫产及新生儿疾病发生情况均高于对照组 (χ2 =4 .0 2～ 81 .31 ,P <0 .0 5、0 .0 1 )。④结论　GIGT对妊娠可造成不同程度的危害 ,GIGT是影响孕妇及围生儿结局的重要因素。对妊娠期GIGT均应进行监测和处理     

佩兰二术汤治疗痰湿型2型糖尿病临床观察

目的观察佩兰二术汤治疗痰湿型2型糖尿病的临床疗效。方法37例2型糖尿病患者给予佩兰二术汤治疗,疗程2个月;观察其临床疗效和治疗前后空腹血糖(FPG)、血脂(TG、TC)的变化。结果临床治愈5例,好转29例,未愈3例,总有效率为91.89%;FPG、TC、TG明显降低(P<0.01)。结论佩兰二术汤治疗痰湿型2型糖尿病疗效确切。     

循环内皮细胞水平与糖尿病肾病的相关性及银杏达莫的干预作用

目的:探讨外周血循环内皮细胞(CEC)和糖尿病肾病(DN)的相关性,以及银杏达莫注射液在DN防治中的可能作用。方法:检测65例2型糖尿病患者24h尿白蛋白排泄率(UAER)及CEC数,分析两者的相关性。将UAER为30~300mg·d-1的45例患者随机分为两组,常规治疗组22例,进行常规降血糖、控制血压等治疗;银杏达莫治疗组23例,在常规治疗基础上静脉滴注银杏达莫注射液2周。比较两组治疗前后血糖、血压、UAER及CEC水平的变化。结果:单纯糖尿病(SDM)组和早期糖尿病肾病(EDN)组的外周血CEC水平比对照组(NC)显著性升高,并呈逐渐增高的趋势(P<0.01)。UAER与收缩压(SBP)、外周血CEC水平呈正相关(P<0.01)。EDN组中,银杏达莫治疗后UAER及CEC明显降低(P<0.01);而常规治疗组无明显变化。线性多元逐步回归分析表明,银杏达莫治疗后UAER的改变与CEC数的变化成正相关(P<0.01)。结论:血管内皮细胞(VEC)损伤在DN发生发展中起重要作用,银杏达莫对VEC的保护作用可能是其延缓DN发展的重要机制。     

糖尿病患者甘油三酯/高密度脂蛋白胆固醇比值水平与胰岛素抵抗的关系

目的探讨血清甘油三酯/高密度脂蛋白胆固醇(TG/HDL-C)比值水平与胰岛素抵抗的关系。方法对146例2型糖尿病患者测定空腹胰岛素(FINS)、空腹血糖(FBG),TG,HDL-C,低密度脂蛋白胆固醇(LDL-C)水平,计算TG/HDL-C比值,并按TG/HDL-C和FBG水平分组,比较组间差异与胰岛素抵抗指数(HOMA-IR)的关系。结果糖尿病组TG/HDL-C比值水平(2.531±3.741)显著高于正常对照组(0.898±0.487),差异有显著性(t=4.279,P<0.001)。TG/HDL-C比值增高组HOMA-IR(3.291±2.004)明显高于TG/HDL-C比值正常组(2.403±1.789),差异有显著性(t=2.796,P<0.01)。血糖水平>10 mmol/L组HOMA-IR(3.575±2.216)明显大于血糖水平≤10mmol/L组(2.384±1.584),差异有显著性(t=3.760,P<0.001)。结论糖尿病患者TG/HDL-C比值水平与胰岛素抵抗存在着密切的相关性。     

灵菊七提取物对糖尿病大鼠治疗作用的实验研究

目的 观察灵菊七提取物对糖尿病大鼠的治疗作用。方法 给大鼠腹腔注射链脲佐菌素，造成糖尿病动物模型，观察不同剂量的灵菊七提取物对正常和糖尿病大鼠体重、血糖、血脂的影响及肾保护作用。结果 灵菊七提取物可显著增加糖尿病大鼠体重，降低血糖，治疗效果优于阳性药物对照组；无明显降血清胆固醇（TC）作用，高剂量组可显著降低甘油三酯（TG）；显著降低糖尿病大鼠Cr、BUN。结论 灵菊七提取物对糖尿病大鼠具一定治疗作用。